                         SEQUENCE LISTING

<110>  Hughes, Patrick M.
       DeVries, Gerald W.
       Lyons, Robert T.
       Trogden, John T.
       Whitcup, Scott M.
 
<120>  High Viscosity Macromolecular Compositions 
       for Treating Ocular Conditions

<130>  18197 (OCU)

<160>  23    

<170>  PatentIn version 3.3

<210>  1
<211>  19
<212>  RNA
<213>  Artificial sequence

<220>
<223>  siRNA

<400>  1
gcgauggccu cuucuguaa                                                  19


<210>  2
<211>  19
<212>  RNA
<213>  Artificial sequence

<220>
<223>  siRNA

<400>  2
ccaugucucg gguccauuu                                                  19


<210>  3
<211>  19
<212>  RNA
<213>  Artificial sequence

<220>
<223>  siRNA

<400>  3
gcuuuacuau ucccagcua                                                  19


<210>  4
<211>  19
<212>  RNA
<213>  Artificial sequence

<220>
<223>  siRNA

<400>  4
gggaauaccc uucuucgaa                                                  19


<210>  5
<211>  19
<212>  RNA
<213>  Artificial sequence

<220>
<223>  siRNA

<400>  5
gcaucagcau aagaaacuu                                                  19


<210>  6
<211>  19
<212>  RNA
<213>  Artificial sequence

<220>
<223>  siRNA

<400>  6
gcugacaugu acggucuau                                                  19


<210>  7
<211>  19
<212>  RNA
<213>  Artificial sequence

<220>
<223>  siRNA

<400>  7
ggaauugaca agacagcaa                                                  19


<210>  8
<211>  19
<212>  RNA
<213>  Artificial sequence

<220>
<223>  siRNA

<400>  8
ccacuuaccu gaggagcaa                                                  19


<210>  9
<211>  19
<212>  RNA
<213>  Artificial sequence

<220>
<223>  siRNA

<400>  9
gcuccugaag aucuguaua                                                  19


<210>  10
<211>  19
<212>  RNA
<213>  Artificial sequence

<220>
<223>  siRNA

<400>  10
gcacgaaaua uccucuuau                                                  19


<210>  11
<211>  576
<212>  DNA
<213>  Homo sapiens

<400>  11
atgaactttc tgctgtcttg ggtgcattgg agccttgcct tgctgctcta cctccaccat     60

gccaagtggt cccaggctgc acccatggca gaaggaggag ggcagaatca tcacgaagtg    120

gtgaagttca tggatgtcta tcagcgcagc tactgccatc caatcgagac cctggtggac    180

atcttccagg agtaccctga tgagatcgag tacatcttca agccatcctg tgtgcccctg    240

atgcgatgcg ggggctgctg caatgacgag ggcctggagt gtgtgcccac tgaggagtcc    300

aacatcacca tgcagattat gcggatcaaa cctcaccaag gccagcacat aggagagatg    360

agcttcctac agcacaacaa atgtgaatgc agaccaaaga aagatagagc aagacaagaa    420

aatccctgtg ggccttgctc agagcggaga aagcatttgt ttgtacaaga tccgcagacg    480

tgtaaatgtt cctgcaaaaa cacagactcg cgttgcaagg cgaggcagct tgagttaaac    540

gaacgtactt gcagatgtga caagccgagg cggtga                              576


<210>  12
<211>  4071
<212>  DNA
<213>  Homo sapiens

<400>  12
atggagagca aggtgctgct ggccgtcgcc ctgtggctct gcgtggagac ccgggccgcc     60

tctgtgggtt tgcctagtgt ttctcttgat ctgcccaggc tcagcataca aaaagacata    120

cttacaatta aggctaatac aactcttcaa attacttgca ggggacagag ggacttggac    180

tggctttggc ccaataatca gagtggcagt gagcaaaggg tggaggtgac tgagtgcagc    240

gatggcctct tctgtaagac actcacaatt ccaaaagtga tcggaaatga cactggagcc    300

tacaagtgct tctaccggga aactgacttg gcctcggtca tttatgtcta tgttcaagat    360

tacagatctc catttattgc ttctgttagt gaccaacatg gagtcgtgta cattactgag    420

aacaaaaaca aaactgtggt gattccatgt ctcgggtcca tttcaaatct caacgtgtca    480

ctttgtgcaa gatacccaga aaagagattt gttcctgatg gtaacagaat ttcctgggac    540

agcaagaagg gctttactat tcccagctac atgatcagct atgctggcat ggtcttctgt    600

gaagcaaaaa ttaatgatga aagttaccag tctattatgt acatagttgt cgttgtaggg    660

tataggattt atgatgtggt tctgagtccg tctcatggaa ttgaactatc tgttggagaa    720

aagcttgtct taaattgtac agcaagaact gaactaaatg tggggattga cttcaactgg    780

gaataccctt cttcgaagca tcagcataag aaacttgtaa accgagacct aaaaacccag    840

tctgggagtg agatgaagaa atttttgagc accttaacta tagatggtgt aacccggagt    900

gaccaaggat tgtacacctg tgcagcatcc agtgggctga tgaccaagaa gaacagcaca    960

tttgtcaggg tccatgaaaa accttttgtt gcttttggaa gtggcatgga atctctggtg   1020

gaagccacgg tgggggagcg tgtcagaatc cctgcgaagt accttggtta cccaccccca   1080

gaaataaaat ggtataaaaa tggaataccc cttgagtcca atcacacaat taaagcgggg   1140

catgtactga cgattatgga agtgagtgaa agagacacag gaaattacac tgtcatcctt   1200

accaatccca tttcaaagga gaagcagagc catgtggtct ctctggttgt gtatgtccca   1260

ccccagattg gtgagaaatc tctaatctct cctgtggatt cctaccagta cggcaccact   1320

caaacgctga catgtacggt ctatgccatt cctcccccgc atcacatcca ctggtattgg   1380

cagttggagg aagagtgcgc caacgagccc agccaagctg tctcagtgac aaacccatac   1440

ccttgtgaag aatggagaag tgtggaggac ttccagggag gaaataaaat tgaagttaat   1500

aaaaatcaat ttgctctaat tgaaggaaaa aacaaaactg taagtaccct tgttatccaa   1560

gcggcaaatg tgtcagcttt gtacaaatgt gaagcggtca acaaagtcgg gagaggagag   1620

agggtgatct ccttccacgt gaccaggggt cctgaaatta ctttgcaacc tgacatgcag   1680

cccactgagc aggagagcgt gtctttgtgg tgcactgcag acagatctac gtttgagaac   1740

ctcacatggt acaagcttgg cccacagcct ctgccaatcc atgtgggaga gttgcccaca   1800

cctgtttgca agaacttgga tactctttgg aaattgaatg ccaccatgtt ctctaatagc   1860

acaaatgaca ttttgatcat ggagcttaag aatgcatcct tgcaggacca aggagactat   1920

gtctgccttg ctcaagacag gaagaccaag aaaagacatt gcgtggtcag gcagctcaca   1980

gtcctagagc gtgtggcacc cacgatcaca ggaaacctgg agaatcagac gacaagtatt   2040

ggggaaagca tcgaagtctc atgcacggca tctgggaatc cccctccaca gatcatgtgg   2100

tttaaagata atgagaccct tgtagaagac tcaggcattg tattgaagga tgggaaccgg   2160

aacctcacta tccgcagagt gaggaaggag gacgaaggcc tctacacctg ccaggcatgc   2220

agtgttcttg gctgtgcaaa agtggaggca tttttcataa tagaaggtgc ccaggaaaag   2280

acgaacttgg aaatcattat tctagtaggc acggcggtga ttgccatgtt cttctggcta   2340

cttcttgtca tcatcctacg gaccgttaag cgggccaatg gaggggaact gaagacaggc   2400

tacttgtcca tcgtcatgga tccagatgaa ctcccattgg atgaacattg tgaacgactg   2460

ccttatgatg ccagcaaatg ggaattcccc agagaccggc tgaagctagg taagcctctt   2520

ggccgtggtg cctttggcca agtgattgaa gcagatgcct ttggaattga caagacagca   2580

acttgcagga cagtagcagt caaaatgttg aaagaaggag caacacacag tgagcatcga   2640

gctctcatgt ctgaactcaa gatcctcatt catattggtc accatctcaa tgtggtcaac   2700

cttctaggtg cctgtaccaa gccaggaggg ccactcatgg tgattgtgga attctgcaaa   2760

tttggaaacc tgtccactta cctgaggagc aagagaaatg aatttgtccc ctacaagacc   2820

aaaggggcac gattccgtca agggaaagac tacgttggag caatccctgt ggatctgaaa   2880

cggcgcttgg acagcatcac cagtagccag agctcagcca gctctggatt tgtggaggag   2940

aagtccctca gtgatgtaga agaagaggaa gctcctgaag atctgtataa ggacttcctg   3000

accttggagc atctcatctg ttacagcttc caagtggcta agggcatgga gttcttggca   3060

tcgcgaaagt gtatccacag ggacctggcg gcacgaaata tcctcttatc ggagaagaac   3120

gtggttaaaa tctgtgactt tggcttggcc cgggatattt ataaagatcc agattatgtc   3180

agaaaaggag atgctcgcct ccctttgaaa tggatggccc cagaaacaat ttttgacaga   3240

gtgtacacaa tccagagtga cgtctggtct tttggtgttt tgctgtggga aatattttcc   3300

ttaggtgctt ctccatatcc tggggtaaag attgatgaag aattttgtag gcgattgaaa   3360

gaaggaacta gaatgagggc ccctgattat actacaccag aaatgtacca gaccatgctg   3420

gactgctggc acggggagcc cagtcagaga cccacgtttt cagagttggt ggaacatttg   3480

ggaaatctct tgcaagctaa tgctcagcag gatggcaaag actacattgt tcttccgata   3540

tcagagactt tgagcatgga agaggattct ggactctctc tgcctacctc acctgtttcc   3600

tgtatggagg aggaggaagt atgtgacccc aaattccatt atgacaacac agcaggaatc   3660

agtcagtatc tgcagaacag taagcgaaag agccggcctg tgagtgtaaa aacatttgaa   3720

gatatcccgt tagaagaacc agaagtaaaa gtaatcccag atgacaacca gacggacagt   3780

ggtatggttc ttgcctcaga agagctgaaa actttggaag acagaaccaa attatctcca   3840

tcttttggtg gaatggtgcc cagcaaaagc agggagtctg tggcatctga aggctcaaac   3900

cagacaagcg gctaccagtc cggatatcac tccgatgaca cagacaccac cgtgtactcc   3960

agtgaggaag cagaactttt aaagctgata gagattggag tgcaaaccgg tagcacagcc   4020

cagattctcc agcctgactc ggggaccaca ctgagctctc ctcctgttta a            4071


<210>  13
<211>  21
<212>  DNA
<213>  Artificial sequence

<220>
<223>  siRNA

<400>  13
accucaccaa ggccagcact t                                               21


<210>  14
<211>  21
<212>  DNA
<213>  Artificial sequence

<220>
<223>  siRNA

<400>  14
gugcuggccu uggugaggut t                                               21


<210>  15
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  VEGF inhibitor

<400>  15

Lys Pro Ser Ser Pro Pro Glu Glu 
1               5               


<210>  16
<211>  123
<212>  PRT
<213>  Artificial sequence

<220>
<223>  anti-VEGF murine monoclonal antibody (variable region of heavy 
       chain)

<400>  16

Glu Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Gln Pro Gly Glu 
1               5                   10                  15      


Thr Val Arg Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
            20                  25                  30          


Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe 
    50                  55                  60                  


Lys Arg Arg Phe Thr Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Ile Ser Asn Leu Lys Asn Asp Asp Thr Ala Thr Tyr Phe Cys 
                85                  90                  95      


Ala Lys Tyr Pro His Tyr Tyr Gly Ser Ser His Trp Tyr Phe Asp Val 
            100                 105                 110         


Trp Gly Ala Gly Ile Thr Val Thr Val Ser Ser 
        115                 120             


<210>  17
<211>  123
<212>  PRT
<213>  Artificial sequence

<220>
<223>  humanized anti-VEGF F(ab) (vanriable region of heavy chain)

<400>  17

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
            20                  25                  30          


Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe 
    50                  55                  60                  


Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Lys Tyr Pro His Tyr Tyr Gly Ser Ser His Trp Tyr Phe Asp Val 
            100                 105                 110         


Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120             


<210>  18
<211>  113
<212>  PRT
<213>  Artificial sequence

<220>
<223>  human consensus framework (variable region of heavy chain)

<400>  18

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Cys Leu Glu Trp Val 
        35                  40                  45              


Ser Val Ile Ser Gly Asp Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser 
            100                 105                 110         


Ser 
    


<210>  19
<211>  108
<212>  PRT
<213>  Artificial sequence

<220>
<223>  anti-VEGF murine mAb (variable region of light chain)

<400>  19

Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 
1               5                   10                  15      


Asp Arg Val Ile Ile Ser Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Val Leu Ile 
        35                  40                  45              


Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Phe Trp 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg 
            100                 105             


<210>  20
<211>  108
<212>  PRT
<213>  Artificial sequence

<220>
<223>  amanized anti-VEGF F(ab) (variable region of light chain)

<400>  20

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile 
        35                  40                  45              


Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg 
            100                 105             


<210>  21
<211>  108
<212>  PRT
<213>  Artificial sequence

<220>
<223>  human consensus framework (variable region of light chain)

<400>  21

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Asn Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Thr 
        35                  40                  45              


Tyr Ala Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Leu Pro Trp 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg 
            100                 105             


<210>  22
<211>  21
<212>  DNA
<213>  Artificial sequence

<220>
<223>  siRNA

<400>  22
cugaguuuaa aaggcaccct t                                               21


<210>  23
<211>  21
<212>  DNA
<213>  Artificial sequence

<220>
<223>  siRNA

<400>  23
ttgacucaaa uuuuccgugg g                                               21


??

??

??

??









D-3157 CIP2	1	PATENT




18197 PCT OCU

Page 2 of 13

18197 PCT OCU

